Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA · Real-Time Price · USD
24.88
+0.04 (0.16%)
At close: May 29, 2026, 4:00 PM EDT
25.37
+0.49 (1.97%)
After-hours: May 29, 2026, 4:44 PM EDT

Damora Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
14.89.6910.512.691313.74
Research & Development
49.98201.1910.7923.7748.2138.49
Other Operating Expenses
--0.973.45--
Total Operating Expenses
64.77210.8722.2639.9161.2152.23
Operating Income
-239.08-210.87-22.26-39.91-61.21-52.23
Interest Income
3.071.170.84---
Other Non-Operating Income (Expense)
4.0910.881.56-0.420.48
Total Non-Operating Income (Expense)
7.162.171.721.56-0.420.48
Pretax Income
-235-209.79-21.4-38.35-61.62-51.75
Provision for Income Taxes
-0.09-0.05-0.04---
Net Income
-235.09-209.84-21.44-38.35-61.62-51.75
Net Income to Common
-235.09-209.84-21.44-38.35-61.62-51.75
Shares Outstanding (Basic)
1011111
Shares Outstanding (Diluted)
1011111
Shares Change (YoY)
689.80%17.79%8.87%4.58%0.58%452.45%
EPS (Basic)
5.283.98-18.53-36.08-60.75-51.25
EPS (Diluted)
5.283.98-18.53-36.08-60.75-51.25
Shares Outstanding
60.31.61.321.081.031.01
Free Cash Flow
-24.89-6.73-18.62-36.91-43.13-52.53
Free Cash Flow Per Share
-2.59-4.93-16.09-34.73-42.43-51.99
EBITDA
-238.99-210.84-22.08-39.08-60.72-51.79
EBIT
-239.08-210.87-22.26-39.91-61.21-52.23
Effective Tax Rate
0.04%0.02%0.19%0.00%0.00%0.00%
SEC Filings: 10-K · 10-Q